INSERM unité mixte de recherche (UMR_S) 1193, F-94800 Villejuif, France.
UMR_S 1193, Université Paris-Sud/Paris-Saclay, F-94800 Villejuif, France.
Cells. 2020 Feb 12;9(2):420. doi: 10.3390/cells9020420.
The liver is a very complex organ that ensures numerous functions; it is thus susceptible to multiple types of damage and dysfunction. Since 1983, orthotopic liver transplantation (OLT) has been considered the only medical solution available to patients when most of their liver function is lost. Unfortunately, the number of patients waiting for OLT is worryingly increasing, and extracorporeal liver support devices are not yet able to counteract the problem. In this review, the current and expected methodologies in liver regeneration are briefly analyzed. In particular, human pluripotent stem cells (hPSCs) as a source of hepatic cells for liver therapy and regeneration are discussed. Principles of hPSC differentiation into hepatocytes are explored, along with the current limitations that have led to the development of 3D culture systems and organoid production. Expected applications of these organoids are discussed with particular attention paid to bio artificial liver (BAL) devices and liver bio-fabrication.
肝脏是一个非常复杂的器官,确保了许多功能;因此,它容易受到多种类型的损伤和功能障碍的影响。自 1983 年以来,原位肝移植(OLT)被认为是大多数肝功能丧失的患者唯一可用的医学解决方案。不幸的是,等待 OLT 的患者数量令人担忧地在增加,而体外肝脏支持设备还无法解决这个问题。在这篇综述中,简要分析了当前和预期的肝脏再生方法。特别地,探讨了人类多能干细胞(hPSC)作为肝脏治疗和再生的肝细胞来源。探讨了 hPSC 分化为肝细胞的原理,以及导致 3D 培养系统和类器官生产发展的当前限制。讨论了这些类器官的预期应用,特别关注生物人工肝脏(BAL)设备和肝脏生物制造。